Asked by: Justin Madders (Labour - Ellesmere Port and Neston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with stakeholders on tackling shortages of atorvastatin.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
There have been supply issues with atorvastatin, but as a result of our work to manage those issues, including engaging with alternative suppliers to cover supply gaps in order to meet demand, they have now been resolved.
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.
Asked by: Justin Madders (Labour - Ellesmere Port and Neston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with relevant stakeholders on tackling shortages of Ezetimibe.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department is aware of supply issues affecting several Ezetimibe suppliers. We are engaging with these suppliers to address the issues, and are working with alternative suppliers to ensure supplies remain available.
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.
Asked by: Justin Madders (Labour - Ellesmere Port and Neston)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with relevant stakeholders on tackling shortages of Etoricoxib.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department is aware that a supplier of etoricoxib 60 milligram tablets is experiencing a supply issue. We have been working with that supplier to address the issue, and resupply is expected in early May 2024. We have worked with alternative suppliers to ensure they can cover the gap in the market in the meantime.
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as other countries around the world. There can be a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
Whilst we can’t always prevent supply issues, the Department has well-established tools and processes to manage them, in order to mitigate risks to patients. We work closely with the pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help ensure patients continue to have access to suitable medicines when supply is disrupted.
Asked by: Lord Randall of Uxbridge (Conservative - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask His Majesty's Government what progress they have made in reforming incentives, including subsidies for ecologically harmful activities, as required under Target 18 of the Global Biodiversity Framework.
Answered by Lord Benyon - Minister of State (Foreign, Commonwealth and Development Office)
In May 2024, the UK plans to publish its National Biodiversity Strategy and Action Plan (NBSAP), which will set out national targets and policies for implementing targets in the Global Biodiversity Framework, including Target 18. This will include a target to identify any incentives and subsidies that are harmful to biodiversity. The UK already has a positive story to tell on reforming incentives through our work to deliver the Agricultural Transition. Our Environmental Land Management schemes will incentivise farmers to improve biodiversity, soil health and air and water quality, reduce agricultural emissions, restore peatland, and establish and restore woodlands and forests.
Asked by: Patrick Grady (Scottish National Party - Glasgow North)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what recent steps his Department has taken with the United Nations to help tackle (a) drug-resistant tuberculosis and (b) antimicrobial resistance.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The department actively contributed to the High Level Meeting on Tuberculosis held at the UN General Assembly last September, at which Lord Ahmad represented the UK. The UK's current £1billion commitment to the Global Fund to Fight AIDS, Tuberculosis and Malaria will support treatment for 41,800 people with Multi-Drug Resistant TB.
The UK funds major programmes and research to tackle Antimicrobial Resistance (AMR), and strengthen health, water, sanitation, and hygiene systems. The High-Level Meeting on AMR is an excellent opportunity to catalyse global progress, set high ambitions across the One Health spectrum, and promote equitable access to and stewardship of antimicrobials.
Asked by: David Mundell (Conservative - Dumfriesshire, Clydesdale and Tweeddale)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what assessment his Department has made of the effectiveness of the Robert Carr Fund in advancing human rights of inadequately served populations.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK is proud to be a long-term funder of the Robert Carr Fund (RCF), we consider it to be a very effective mechanism that supports the leadership, priorities and rights of some of the most marginalised people, in order to expand their access to the HIV, SRHR and health services they need.
Robert Carr is the world's leading international fund focused on funding global and regional networks led by, involving, and serving people who face a higher HIV risk than the general population, systematic human rights violations, and barriers to information and HIV and SRH services.
Working with community-led and grassroots organisations is key to achieving the targets in the Global AIDS Strategy. Our investment into the Robert Carr Fund, along with other organisations such as the Global Fund and UNAIDS, is important in helping countries to implement actions and make progress towards targets under the Strategy.
Asked by: David Mundell (Conservative - Dumfriesshire, Clydesdale and Tweeddale)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what assessment his Department has made of the potential merits of funding the Robert Carr Fund to support the achievement of the targets in the UNAIDS Global AIDS Strategy 2024-27.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK is proud to be a long-term funder of the Robert Carr Fund (RCF), we consider it to be a very effective mechanism that supports the leadership, priorities and rights of some of the most marginalised people, in order to expand their access to the HIV, SRHR and health services they need.
Robert Carr is the world's leading international fund focused on funding global and regional networks led by, involving, and serving people who face a higher HIV risk than the general population, systematic human rights violations, and barriers to information and HIV and SRH services.
Working with community-led and grassroots organisations is key to achieving the targets in the Global AIDS Strategy. Our investment into the Robert Carr Fund, along with other organisations such as the Global Fund and UNAIDS, is important in helping countries to implement actions and make progress towards targets under the Strategy.
Asked by: David Mundell (Conservative - Dumfriesshire, Clydesdale and Tweeddale)
Question to the Foreign, Commonwealth & Development Office:
To ask the Minister of State, Foreign, Commonwealth and Development Office, what assessment his Department has made of the effectiveness of the Robert Carr Fund in advancing HIV and health outcomes for inadequately served populations.
Answered by Andrew Mitchell - Minister of State (Foreign, Commonwealth and Development Office) (Minister for Development)
The UK is proud to be a long-term funder of the Robert Carr Fund (RCF), we consider it to be a very effective mechanism that supports the leadership, priorities and rights of some of the most marginalised people, in order to expand their access to the HIV, SRHR and health services they need.
Robert Carr is the world's leading international fund focused on funding global and regional networks led by, involving, and serving people who face a higher HIV risk than the general population, systematic human rights violations, and barriers to information and HIV and SRH services.
Working with community-led and grassroots organisations is key to achieving the targets in the Global AIDS Strategy. Our investment into the Robert Carr Fund, along with other organisations such as the Global Fund and UNAIDS, is important in helping countries to implement actions and make progress towards targets under the Strategy.
Asked by: Matt Western (Labour - Warwick and Leamington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure people with diabetes can continue to access the insulin they need.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are aware of supply issues with some insulin products, however the vast majority are in stock. Comprehensive management guidance on alternative products has been issued to the National Health Service where needed.
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as the other countries around the world, and it can have a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
There is a team within the Department that deals specifically with medicine supply problems. It has well-established tools and processes to manage medicine supply issues, working closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, and others operating in the supply chain, to help prevent shortages and expedite resupply as soon as possible, to ensure that the risks to patients are minimised.
Asked by: Gen Kitchen (Labour - Wellingborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she plans to enable the provision of additional services in GP surgeries in Wellingborough constituency.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
All practices can opt in to providing Enhanced Services, as well as Direct Enhanced Services for which practices are paid separately from the global sum payment. Integrated care boards, as commissioners of primary care, are responsible for commissioning Local Enhanced Services, which vary in scope and funding to fit the needs of local areas.